It's No Secret...
Wall Street Rewards
Successful Companies
Martin Nutraceuticals is developing new and
innovative products aimed at the largest sectors
of the HUGE nutraceutical market!
Martin Nutraceuticals Inc. -- OTC.PK: MNCL |
Here’s an exceptional opportunity for intelligent investors in the surging billion dollar nutraceutical industry.
With products aimed at the largest sectors of the market – arthritis or joint plain, anti-oxidants and weight loss, the company is positioned for extraordinary explosive growth.
Martin Nutraceuticals Inc. (OTC.PK MNCL) is ideally positioned for outstanding growth because of three compelling factors:
The knowledge and recognition of Dr. Anthony Martin Sr. (Tony), one of the most recognizable names in the industry.
The exciting new supplemental products created by Dr. Martin.
Martin Nutraceuticals’ ability to bring the products to market.
Dr. Martin -- Author,
Speaker and Industry Expert
Dr. Anthony Martin, D.C., Ph.D., R.N.C.P, D.N.M. brings over 30 years of Naturopathic and Supplementation experience to Martin Nutraceuticals. Dr. Martin has been involved in medicine since the early 1970’s and in 1997, Martin became a Doctor of Natural Medicine. He is certified by the Examining Board of Natural Medicine Practitioners.
Dr. Martin is one of the most sought after speakers on the topic in Nutraceuticals in the world. Dr. Martin has regularly conducted seminars throughout North America to audiences tallying over 50,000.
He has
authored many books in the field of nutraceuticals and has appeared before television and radio stations audiences estimated to be in excess of 26 million, speaking on the topic of nutraceuticals and Chronic Fatigue Syndrome.
This strong industry identification provides Martin Nutraceuticals’ products instant brand recognition that will help to propel the company’s growth.
New Marketing Campaign
The company is off to a great start with its latest marketing campaign in Quebec, the largest Province in Canada. The company's new infomercial is focused in an
area where Dr. Martin's presence is well-recognized. Dr. Martin's presence and recognition has translated into immense marketing success in the past and the infomercial is currently generating a great anticipation among Quebec's retailers with the introduction of Dr. Martin's new line of improved and tested products.
Extensive New Product Line
Joining Dr. Martin’s Joint Therapy, which has contributed to helping thousands of people overcome pain and suffering related to arthritis and joint pain, are revolutionary
new products including:
Arthrizyme, Digestzyme, Heartzyme, Petzyme, Oxygenol, Maximum Slim and Probiotix.
Arthrizyme is Martin Nutraceuticals’ primary product offering. Arthrizyme is an all natural, unique blend of systemic enzymes designed to provide superior anti-inflammatory benefits, by breaking down harmful protein and facilitating its removal from the body. To aid in the reduction of inflammation, Arthrizyme also has been shown to have an effect on improving the blood flow and regulating the immune system, which in turn assists the human body in accelerating the healing process.
Dr. Martin’s Oxygenol formula
is a water-soluble, antioxidant formula extracted from a particular species of Canadian pine bark extract extremely high in bioflavonoids. These bioflavonoids are particularly favorable, due to their nature of blocking unwanted, undesirable compounds in the body. Because it is 50 times more powerful than vitamin E and 20 times more powerful than vitamin C, the Oxygenol formula has become a mainstay in the treatment of several chronic illnesses.
Dr. Martin's Maximum Slim formula consists of capsules, ampoules containing NeoPuntia, a ready-mix drink and a beverage mix. Utilizing NeoPuntia - the dietary fiber taken from the Nopal plant, Dr. Martin has developed the Maximum Slim to bind fat from food, therefore preventing
fat from being absorbed by the body. This in turn suppresses hunger and increases metabolism in a safe and effective way.
Dr. Martin's Digestzyme is for bloating, indigestion, heartburn, gas, stomach or intestinal pain…all digestive problems that can be solved with the use of Digestzyme - a product developed with the use of the strongest enzymes available today. Digestzyme has been formulated to drastically improve digestion and nutrient absorption.
In addition to these products, Dr. Martin’s joint therapy and digestive therapy products share a significant marketing advantage because they use an oral systemic enzyme in their formulation
that helps in the absorption of the products. It is this feature that significantly distinguishes these Dr. Martin products from their competition.
With this diverse family of products, Martin Nutraceuticals offers consumers natural alternatives for the growing concerns of general joint pain, increasing the activity of the immune system, increasing alertness/awareness and obesity control.
Investor Prospects
Martin Nutraceuticals
Inc. (OTC.PK: MNCL) has the ingredients for success in the huge and rapidly growing nutraceutical market. They have a strong management team, along with key industry name recognition through their product’s namesake, Dr. Martin and key innovative products aimed at the largest sectors of the nutraceutical market – arthritis/joint plain, anti-oxidants and weight loss.
Dr. Martin's name recognition will immediately associate familiarity with Martin Nutraceuticals and the actual products themselves should maintain sustained growth of the company. Using patented and proprietary oral systemic enzymes, Martin Nutraceuticals is quickly establishing itself as a category leader in the nutraceutical marketplace.
This growth will likely produce superior returns
for intelligent investors recognizing
Martin Nutraceuticals' exciting potential.
For additional information on Martin Nutraceuticals contact:
Aurora Venture Communications Group
Toll Free: 1-(866)-360-1643
Email: MNCL@avcg.net
Web: www.avcg.net/profile/MNCL
Disclaimer: This publicly distributed email is a sponsored advertisement. This is a publication of OTC Platinum Report, a financial communications and investor relations company. OTC Platinum Report administered a fifty thousand dollar budget to assist in administration and execution of this advertising effort. This is not an offer to buy or sell securities. Information or opinions in this report are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution
or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. Companies mentioned herein may carry a high investment risk; readers should carefully review the companies thoroughly with their registered investment advisor or registered stockbroker. We are not liable for any investment decisions by our readers. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at http://www.sec.gov and the National Association of Securities Dealers (NASD) at http://www.nasd.com. The NASD has published information on how to invest carefully at its web site. Readers can review all public filings by companies at the SEC's EDGAR
page. All information within this report is qualified in its entirety by the detailed information and financial statements of the advertised company contained in its regulatory filings with the SEC. The analysis contained herein does not purport to be a complete study of the featured Company or other companies mentioned. Information used and statements have been obtained from public sources, but not verified nor guaranteed by OTC Platinum Report as to completeness or accuracy. Such information is subject to change without notice. It should be understood that there is no guarantee past performance will be indicative of future results. Opinions stated herein may be solely OTC Platinum Report or the indicated source's, and not necessarily those of the featured Company. Officers, directors, and
employees of OTC Platinum Report and financial analysts mentioned, and members of their families may hold a position and may, from time to time, trade in these securities for their own accounts. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. © 2006 OTC Platinum Report. All rights reserved. Duplication of this report without the expressed written permission of OTC Platinum Report is strictly prohibited. This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are
not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties,
many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
Advertiser:
OTC Platinum Advisor
Apartado 10455-1000
San Jose Costa Rica
Disclaimer This profile published by OTC Live, Inc is an independent electronic publication providing information and factual analysis on selected companies. All statements and expressions are the opinion of OTC Live, Inc and are not meant to be either investment advice or a solicitation or recommendation to buy, sell, or hold securities. Investing in micro-cap securities is highly speculative and carries
an extremely high degree of risk. OTC Live, Inc is not a broker dealer or a registered investment advisor . It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Profiles rely on information provided by the featured Companies and/or Edgar filings. While OTC Live, Inc believes its sources to be reliable, associates of OTC Live, Inc, or any affiliated parties make no representation or warranty as to the accuracy of the information provided. Readers should not rely solely on the information contained in this publication, but should consult with their own independent tax, business and financial advisors with respect to any investment opportunity, including any contemplated investment in the advertised Company. Factual statements
in this publication are made as of the date stated and are subject to change without notice. OTC Live, Inc is not responsible for any claims made by the Company. We have prepared this report, drawing upon a range of public news, the company's website and information from sources in the industry, as well as data and opinions provided by the company. Prior to issuing this report, the Company reviewed and approved the contents in writing hereof. OTC Live, Inc has not independently verified the Company's representations. Any opinions expressed in this report are statements of judgment as of the date of publication. We urge readers to carefully verify all presentations within the report independently. The receipt of this publication shall not create, under any circumstances, any implication that
there has been no change in the affairs of the company profiled since the date of review. This advertisement does not provide an analysis of the Company's financial position. OTC Live, Inc of this advertisement has been compensated seven thousand dollars by a third party for the preparation and electronic dissemination of this report. This should be viewed as a potential conflict of interest. Furthermore, associates of OTC Live, Inc may have stock positions on profiled companies from time to time. We may profit in the event the shares of the Company profiled by us increase in value. These positions may be liquidated from time to time even after we have made positive comments regarding the Company. The receipt of this information constitutes your acceptance of these terms and conditions. SAFE
HARBOR FOR FORWARD-LOOKING STATEMENTS: Except for historical information contained herein, the statements on this website and newsletter are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition and risk inherent in the companies operations. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ``anticipate,'' ``estimate,'' ``expect,'' ``project,''
``intend,'' ``plan,", "anticipate", "guess", "think", "hear", "suggest", ``believe,'' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. As a suggestion, "Never, ever, make an investment based solely on what you read in an online newsletter or Internet bulletin board, especially if the investment involves a small, thinly-traded company that isn't well known," said Nancy M. Smith, Director of SEC's Office of Investor Education and Assistance. "Assume that the information about these companies is not trustworthy unless you can prove otherwise through your own independent research." "Internet Fraud" is available on the SEC's Web Site, at
http://www.sec.gov/consumer/cyberfr.htm.
